Literature DB >> 33613506

Isopropoxy Benzene Guanidine Kills Staphylococcus aureus Without Detectable Resistance.

Xiufeng Zhang1,2, Wenguang Xiong1,2, Xianfeng Peng3, Yixing Lu1,2, Jie Hao1,2, Zonghua Qin3, Zhenling Zeng1,2.   

Abstract

Serious infections caused by multidrug-resistant Staphylococcus aureus clearly urge the development of new antimicrobial agents. Drug repositioning has emerged as an alternative approach that enables us to rapidly identify effective drugs. We first reported a guanidine compound, isopropoxy benzene guanidine, had potent antibacterial activity against S. aureus. Unlike conventional antibiotics, repeated use of isopropoxy benzene guanidine had a lower probability of resistance section. We found that isopropoxy benzene guanidine triggered membrane damage by disrupting the cell membrane potential and cytoplasmic membrane integrity. Furthermore, we demonstrated that isopropoxy benzene guanidine is capable of treating invasive MRSA infections in vivo studies. These findings provided strong evidence that isopropoxy benzene guanidine represents a new chemical lead for novel antibacterial agent against multidrug-resistant S. aureus infections.
Copyright © 2021 Zhang, Xiong, Peng, Lu, Hao, Qin and Zeng.

Entities:  

Keywords:  isopropoxy benzene guanidine; membrane damage; multidrug-resistant Staphylococcus aureus; resistance section; transcriptome

Year:  2021        PMID: 33613506      PMCID: PMC7890237          DOI: 10.3389/fmicb.2021.633467

Source DB:  PubMed          Journal:  Front Microbiol        ISSN: 1664-302X            Impact factor:   5.640


  3 in total

1.  Pharmacokinetics and Pharmacodynamics of Colistin Combined With Isopropoxy Benzene Guanidine Against mcr-1-Positive Salmonella in an Intestinal Infection Model.

Authors:  Lingli Kong; Yixing Lu; Liuye Yang; Wanying Zhang; Beini Zuo; Xianfeng Peng; Zonghua Qin; Miao Li; Zhenling Zeng; Dongping Zeng
Journal:  Front Microbiol       Date:  2022-05-20       Impact factor: 6.064

2.  Enhancement of the oral bioavailability of isopropoxy benzene guanidine though complexation with hydroxypropyl-β-cyclodextrin.

Authors:  Yixing Lu; Liuye Yang; Wanying Zhang; Shiting Xie; Feifei Zhao; Xianfeng Peng; Zonghua Qin; Dongping Zeng; Zhenling Zeng
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

3.  Pharmacokinetics and pharmacodynamics of isopropoxy benzene guanidine against Clostridium perfringens in an intestinal infection model.

Authors:  Yixing Lu; Liuye Yang; Wanying Zhang; Jie Li; Xianfeng Peng; Zonghua Qin; Zhenling Zeng; Dongping Zeng
Journal:  Front Vet Sci       Date:  2022-09-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.